A standardized approach to the Fugl-Meyer assessment and its implications for clinical trials. by See, Jill et al.
UC Irvine
UC Irvine Previously Published Works
Title
A standardized approach to the Fugl-Meyer assessment and its implications for clinical 
trials.
Permalink
https://escholarship.org/uc/item/59x8z7kn
Journal
Neurorehabilitation and neural repair, 27(8)
ISSN
1545-9683
Authors
See, Jill
Dodakian, Lucy
Chou, Cathy
et al.
Publication Date
2013-10-01
DOI
10.1177/1545968313491000
License
https://creativecommons.org/licenses/by/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Neurorehabilitation and
Neural Repair
27(8) 732 –741
© The Author(s) 2013
Reprints and permissions: 
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1545968313491000
nnr.sagepub.com
Clinical Research Article
Introduction
Motor deficits are among the most common after stroke1,2 and 
thus are a major contributor to stroke disability. A number of 
restorative therapies have been examined for the ability to 
improve motor outcome.3 A key factor in assessing therapeu-
tic efficacy is the choice of behavioral outcome measure. In 
restorative stroke studies, as with acute stroke, outcome mea-
sures need to be valid, reliable, and responsive to change.4,5
A number of clinical trials focused on motor outcomes 
after stroke have employed the Fugl-Meyer Motor 
Assessment (FMA). The FMA was designed by Fugl-Meyer 
et al6 to provide a numeric score of motor status after stroke 
based on the sequential stages of motor recovery described 
by Twitchell,7 Reynolds et al,8 and Brunnstrom9 using mea-
sures such as limb synergy and range of motion.6 The FMA 
has been found to be valid10,11 and reliable.6,11-13 The FMA 
has received increasing attention as a clinical trial outcome 
measure, in part because it has been found to be sensitive to 
behavioral gains in the setting of wide-ranging interven-
tions that include pharmacological compounds,14,15 robot-
ics,16,17 brain stimulation,18,19 constraint-induced therapy,20 
neuromuscular stimulation,21 mental practice,22 and virtual 
reality therapy.23 Consistent with this, a search of PubMed 
using “Fugl-Meyer” and “clinical trial” yields 200 refer-
ences; searching with the same 2 terms on www.clinicaltri-
als.gov yields 125 studies.
A number of issues complicate use of the FMA in clini-
cal trials, however, and motivate the current report. First, 
the FMA was described as having the goal to standardize 
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Abstract
Background. Standardizing scoring reduces variability and increases accuracy. A detailed scoring and training method for 
the Fugl-Meyer motor assessment (FMA) is described and assessed, and implications for clinical trials considered. Methods. 
A standardized FMA scoring approach and training materials were assembled, including a manual, scoring sheets, and 
instructional video plus patient videos. Performance of this approach was evaluated for the upper extremity portion. 
Results. Inter- and intrarater reliability in 31 patients were excellent (intraclass correlation coefficient = 0.98-0.99), validity 
was excellent (r = 0.74-0.93, P < .0001), and minimal detectable change was low (3.2 points). Training required 1.5 hours 
and significantly reduced error and variance among 50 students, with arm FMA scores deviating from the answer key by 
3.8 ± 6.2 points pretraining versus 0.9 ± 4.9 points posttraining. The current approach was implemented without incident 
into training for a phase II trial. Among 66 patients treated with robotic therapy, change in FMA was smaller (P ≤ .01) at the 
high and low ends of baseline FMA scores. Conclusions. Training with the current method improved accuracy, and reduced 
variance, of FMA scoring; the 20% FMA variance reduction with training would decrease sample size requirements from 
137 to 88 in a theoretical trial aiming to detect a 7-point FMA difference. Minimal detectable change was much smaller than 
FMA minimal clinically important difference. The variation in FMA gains in relation to baseline FMA suggests that future 
trials consider a sliding outcome approach when FMA is an outcome measure. The current training approach may be useful 
for assessing motor outcomes in restorative stroke trials.
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patient assessment. However, key operational details of test 
administration were not included by Fugl-Meyer et al,6 rais-
ing uncertainty as to consistency of FMA scores across sites 
and time. Two publications have outlined protocols for 
scoring FMA24,25; however, omission of key operational 
details for administering the test and for scoring patient 
responses limits the extent to which these protocols stan-
dardize patient assessment with the FMA. The importance 
of standardizing methods for scoring outcome measures in 
stroke trials continues to be emphasized26-28; training mate-
rials are needed toward this goal, a perspective that was the 
underlying goal of the current report. Second, the structure 
of the FMA creates uncertainties regarding its use in a clinical 
trial setting. For example, the FMA is not truly linear—a gain 
of points at the bottom versus the top end of the scale has 
different meaning. Also, prior studies have been divided as 
to the extent of floor and ceiling effects with the FMA.11,29-31 
As a result, it is unclear whether the FMA performs equally 
well as an outcome measure across the full spectrum of 
poststroke motor deficits, and how the FMA performs as a 
stratifying variable.32
These issues are addressed in the current report. First, 
detailed definitions and training methods for scoring the 
FMA in a standardized manner are presented, based directly 
on the method described by Fugl-Meyer et al6; note that the 
instructional video, test patient videos, and standardized 
scoring sheets associated with this approach are provided in 
the supplementary material available at http://nnr.sagepub.
com/content/by/supplemental-data. The current approach 
was created and evaluated during 2006-2009, prompted by 
observation of differences in FMA scores across examiners 
on our team. Second, for the upper extremity, the reliability, 
minimal detectable change (MDC), and validity of this test-
ing approach are described herein. Performance of the total 
FMA, proximal arm subsection, and distal arm (wrist/hand) 
subsection are each examined separately, to increase the 
granularity of the FMA for detecting differences between 
patients. Third, the effect of training with this approach is 
examined, including effect on precision and on variance of 
FMA scoring, with consideration of power and sample size 
in a clinical trial context. Fourth, the performance of FMA 
score as a stratifying variable was assessed in patients 
receiving arm motor robotic therapy. Fifth, the experience 
of implementing this scoring approach in a phase II clinical 
trial of stroke recovery is reviewed.
Methods
Design and Content of the Current Approach
The FMA consists of 33 items for the upper extremity and 
17 for the lower extremity. Each item is scored on a 3-point 
ordinal scale (0, 1, or 2), with 0 generally corresponding to 
no function, 1 to partial function, and 2 to perfect function. 
The items are summed to provide a final score, with maxi-
mum score (no impairment) of 66 points for the upper 
extremity and 34 points for the lower extremity.
In the FMA testing approach presented herein, one side 
of the body is tested/scored, and then the other body side is 
tested/scored. For each test item, the initial subject limb 
position is described, testing materials are listed, specific 
instructions to be read to the patient are provided, specific 
assessor movements and amount of assistance that may be 
provided are outlined, then the specific details by which 
each item is scored are provided. The score is based on best 
performance. The task is to be performed within a reason-
able time frame, with 20 seconds per attempt used as a cut-
off based on experience, and a maximum of 3 attempts per 
test item. No special considerations in scoring are made for 
presence of amputation, contracture, prosthesis, aphasia, or 
orthopedic problems.
A total of 10 items were generated in support of this 
FMA scoring approach, each of which is provided in the 
online supplementary material available at http://nnr.sage 
pub.com/content/by/supplemental-data:
1. Arm FM reference manual: Provides the details of 
the approach for the arm, useful to have at one’s side 
when formally assessing patients on the FMA
2. Arm FM scoring sheet: Provides a standardized 
sheet for scoring the arm FMA; printing multiple 
copies for formally assessing patients on the FMA is 
suggested
3. Arm FM training video: Provides video examples of 
a patient being scored on the arm FMA, part of 
training to standardize FMA scoring
4. Arm FM training video guide: Provides written 
explanations to assist with the video
5. Arm FM test subject 1 video: A patient with stroke 
(arm FM score = 30) is to be assessed by trainees 
while watching this video, can be used as part of 
FMA training
6. Arm FM test subject 1 answer key: Reviewed after 
assessing the subject 1 video, this key provides cor-
rect scores and explanations of scoring as deter-
mined by the 5 experienced therapists (JS, LD, CC, 
VC, AMcK) of this project
7. Arm FM test subject 2 video: A second patient with 
stroke (arm FM score = 46) is to be assessed by 
trainees while watching, also useful as part of FMA 
training
8. Arm FM test subject 2 answer key: Reviewed after 
assessing the subject 2 video, this key provides cor-
rect scores and explanations of scoring as deter-
mined by the 5 experienced therapists (JS, LD, CC, 
VC, AMcK) of this project
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 9. Leg FM reference manual: Provides the details of 
the approach for the leg
10. Leg FM scoring sheet: Provides a standardized sheet 
for scoring the leg FMA
The 2 patients were selected for the videos because 
they have mid-range scores and because each permits 
demonstration of several key distinctions in FMA scoring. 
Answer key scores for these two patients were based on 
the FMA testing approach described herein, with maxi-
mum adherence to the principles described in the original 
FMA article,6 and were derived from group discussions 
among study therapists. Two training components related 
to the leg (items 9 and 10 above) are included, although 
current analyses are focused on components related to the 
arm (items 1-8).
The recommended standardized arm FMA training pro-
cedure proposed herein is to (a) review the reference man-
ual and scoring sheet, (b) watch the subject 1 video and 
score this patient, (c) watch the training video with the 
video guide at hand, (d) watch the subject 2 video and score 
this patient, and then (e) review the two answer keys and 
note scoring discrepancies. The time to complete this train-
ing procedure is estimated to be 1.5 hours.
All studies described in the current report were approved 
by the University of California, Irvine, Institutional Review 
Board. All patients provided informed consent.
Reliability, Minimal  
Detectable Change, and Validity
Patients were recruited from 2 robotic studies of arm motor 
therapy33,34 that enrolled adults with a chronic (>3 months 
prior) stroke, arm motor deficits, and no severe deficits in 
language or attention. One of the 2 studies required that the 
motor deficits be right-sided. A total of 31 patients were 
recruited, providing 80% power at α = .05 to detect an intra-
class correlation coefficient (ICC) of 0.91.35 The reliability 
and validity evaluations were shared across 2 physical thera-
pists and an occupational therapist, each of whom had at 
least 10 of years experience in assessing stroke patients and 
each of whom also had participated in creating the current 
FMA manual and training materials. Reliability assessments 
were obtained prior to initiating robotic therapy. For intra-
rater reliability, each of the 31 patients received 2 exams 
from one of the therapists, 1 week apart; for 4 patients, a 
second therapist was available to provide an additional inde-
pendent intrarater reliability assessment, bringing the total 
number of intrarater assessments to a total of 35. For inter-
rater reliability, patients underwent 2 independent exams, 
performed by different therapists, separated by <1 hour. 
Four patients were unable to undergo this added testing, 
bringing the total number of interrater assessments to 27.
To assess FMA validity, at one of the sessions, an exam-
iner also scored 6 other motor-related assessments: grip 
strength,36 pinch strength,37 Box & Blocks38, the Action 
Research Arm Test (ARAT),39 9-hole peg,40 and the Stroke 
Impact Scale (SIS) hand subscore (SIS II, Q 7a-7e).41 These 
6 were selected to capture the diverse dimension of stroke 
effects on the arm motor system, and include tests of body 
function and of activities limitations, tests that are patient-
reported as well as tests that are examiner-based, and tests 
of the proximal arm and of the distal arm. These exams 
were performed on 12 of the patients, at each of 4 separate 
visits across the treatment period, for a total of 48 exams 
focused on validity.
Effect of Training on Accuracy and Variance of 
Fugl-Meyer Assessment Scoring
Students (n = 50) in the Chapman University DPT program 
were trained in the arm FMA using the recommended arm 
FMA training approach described above. Thus, each stu-
dent scored a video of a stroke patient before and again after 
undergoing training on the arm FMA using the current 
approach. Pretraining, each student watched one of the Arm 
FM test subject videos (half watching subject 1 first, half 
watching subject 2 first) and completed an arm FM scoring 
sheet, pausing the video after each task for additional time 
to score, if needed. Next, each student was trained by watch-
ing the Arm FM training video with the Arm FM training 
video guide at hand, and reviewed the Arm FM reference 
manual. Finally, each student was then tested posttraining 
by watching the remaining Arm FM test subject video (eg, 
watched subject 2 video posttraining if the subject 1 video 
had been completed pretraining) then completing a second 
Arm FM scoring sheet, pausing as needed. At the end of 
scoring, students were provided with items 6 and 8 above 
(ie, the Arm FM test subject 1 answer key and the Arm FM 
test subject 2 answer key), and in this way the students’ 
scores were compared with the correct scores that were 
determined by the 5 experienced therapists (JS, LD, CC, 
VC, AMcK) of this project.
Ability of the Fugl-Meyer Assessment to Perform 
as a Stratifying Variable
In 66 patients with chronic stroke enrolled in 1 of 3 studies 
using robotic therapy to improve arm motor function in chronic 
stroke (clinicaltrials.gov identifier: NCT01244243),17,33 
arm motor FMA scores were measured at baseline and 1 
month after a course of robot therapy. These studies enrolled 
adults with a chronic (>3 months prior) stroke, arm motor 
deficits, and no severe deficits in language or attention. 
FMA scores were obtained by 1 of the 5 experienced thera-
pists (JS, LD, CC, VC, AMcK) of this project. The ability of 
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baseline FMA score to stratify patients according to treat-
ment gains was examined by studying the relationship 
between FMA baseline and change scores.
Implementation in a Clinical Stroke Trial
All 10 training materials were provided to the 11 United 
States, Canada, and Germany enrollment sites as part of pre-
trial training for the clinical stroke trial “A Single-Blind 
Study of the Safety, Pharmacokinetics and Pharmacodynamics 
of Escalating Repeat Doses of GSK249320 in Patients With 
Stroke” (clinicaltrials.gov identifier NCT00833989), which 
compared GSK249320, a humanized monoclonal antibody 
that neutralizes MAG (myelin-associated glycoprotein)-
mediated inhibition, with placebo. The FMA was among the 
secondary endpoints of this safety trial. Sites were asked to 
review the Arm FM reference manual, Arm FM scoring 
sheet, Arm FM training video, and Arm FM training video 
guide as part of trial participation. This part of the study 
examined the feasibility of broad implementation of the cur-
rent FMA training procedure. The measure examined in 
relation to this goal was the number of problems or issues 
that were reported to the study sponsor in relation to FMA 
training.
Statistics
Two-tailed statistical methods were used and, except for 
the polynomial statistics in the stratification analyses, 
were nonparametric. Intra- and interrater reliabilities 
were assessed using Spearman’s rank order correlation, 
ICC, and MDC. MDC was assessed as the MDC
90
,42 
which indicates the 90% confidence interval that the mag-
nitude of measurement variability will be less than the 
MDC values. Validity was measured by comparing the 
FMA score with each of the 6 motor-related assessments 
of interest (grip strength, pinch strength, Box & Blocks, 
ARAT, 9-hole peg, and SIS hand subscore), using 
Spearman’s rank order correlation. Reliability and valid-
ity were each evaluated for the total arm FMA, proximal 
arm portion of the FMA, and distal arm (hand/wrist) por-
tion of the FMA. For analysis of the standardization pro-
cedures, differences between students’ scores and the 
answer key pretraining were evaluated for significance by 
performing a 1-sample Wilcoxon signed-rank test to 
determine whether these differences were significantly 
different from zero. This was then repeated for values 
obtained posttraining. The stratification study examined 
the relationship that total arm FMA score at baseline had 
with the change in total arm FMA score across the period 
of therapy. Initial analysis tested for a linear relationship 
using Spearman’s rank order correlation. Visual inspec-
tion of the data suggested a second-order relationship, 
which was tested using a quadratic (polynomial) fit. Post 
hoc testing extended this observation by testing whether 
change in total arm FMA score across therapy differed 
significantly according to baseline score using the 
Wilcoxon rank sums test. Analyses used JMP 5.0 (SAS, 
Cary, NC). ICC analyses used online tools (http://depart 
ment.obg.cuhk.edu.hk/researchsupport/IntraClass_corre 
lation.asp).
Results
Reliability and Validity
Characteristics for the 31 patients appear in Table 1.
For the total arm FMA, reliability (Table 2) was excel-
lent using the scoring approach described herein. For intr-
arater reliability, Spearman’s r = 0.99 (P < .0001), ICC = 
0.99, and MDC
90
 = 3.2 points (4.8% of the highest possi-
ble score). For interrater reliability, r = 0.97 (P < .0001), 
Table 1. Stroke Patients Assessed in Reliability Studies.
n 31
Age in years (mean ± SD) 61.1 ± 12.2
Gender (%)  
 Male 58
 Female 42
Affected side (%)  
 Right 87
 Left 13
Handedness  
 Right 92
 Left 8
Time poststroke in months (mean ± SD) 54 ± 47
Total NIHSS score; median (IQR) 5 (4-7)
Baseline FMA score (mean ± SD) 31.0 ± 14.5 (range 13-58)
Abbreviations: SD, standard deviation; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; FMA, Fugl-Meyer Assessment.
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ICC = 0.99, and MDC
90
 = 3.2 points (which is 4.8% of the 
highest possible score).
For the portion of the FMA corresponding to proximal 
arm motor function, for intrarater reliability, r = 0.99 (P < 
.0001), ICC = 0.99, and MDC
90
 = 1.7 points (4.7% of the 
highest possible score). For interrater reliability, r = 0.95 (P 
< .0001), ICC = 0.98, and MDC
90
 = 1.6 points (4.4% of the 
highest possible score).
For the portion of the FMA corresponding to hand/wrist 
(distal arm) motor function, for intrarater reliability, r = 
0.94 (P < .0001), ICC = 0.99, and MDC
90
 = 1.7 points (7.1% 
of the highest possible score). For interrater reliability, r = 
0.85 (P < .0001), ICC = 0.98, and MDC
90
 = 2.5 points 
(10.4% of the highest possible score).
Validity was also excellent (Table 3), for example, 
Spearman’s r values for the total arm FMA score ranged 
from 0.74 to 0.93. The total arm FMA score, FMA proximal 
subscore, and FMA hand/wrist subscore each correlated 
significantly (P < .0001 in all cases) with each of the diverse 
motor assessments, including patient-reported outcomes 
(SIS hand subscore), distal motor function (9-hole peg, grip 
force, and pinch), and combined distal and proximal (Box 
& Blocks and ARAT) assessments.
Effect of the Standardized Training Procedure 
on Accuracy and Variance of Fugl-Meyer Scoring
Of the 50 students, a posttesting survey disclosed that only 
one had ever administered the arm FMA previously, on a 
single occasion. Participation in the standardized training 
procedure significantly improved accuracy. Pretraining, the 
difference between students and the answer key score was 
3.8 ± 6.2 (mean ± SD) points for the total arm FMA (stu-
dents underscored compared with the answer key), 2.6 ± 3.8 
for the proximal FMA (students underscored), and 0.1 ± 3.8 
for the wrist/hand FMA (students overscored). The total 
arm FMA and proximal FMA values were each signifi-
cantly different from zero (P < .0001), indicating that the 
students deviated significantly from the answer key. 
Posttraining, the difference between students and the answer 
key score was 0.9 ± 4.9 points for the total arm FMA (a 20% 
decrease in SD), 0.7 ± 2.8 for the proximal FMA, and 0.16 
Table 2. Reliability Studies.
Test FMA Total Score FMA Proximal Subscore FMA Hand/Wrist Subscore
Intrarater reliability  
 Spearman’s ra 0.99 0.99 0.94
 ICC 0.99 0.99 0.99
 MDC
90
3.2 points 1.7 points 1.7 points
Interrater reliability  
 Spearman’s ra 0.97 0.95 0.85
 ICC 0.99 0.98 0.98
 MDC
90
3.2 points 1.6 points 2.5 points
Abbreviations: FMA, Fugl-Meyer Assessment; ICC, intraclass correlation coefficient; MDC
90
, 90% confidence interval that the magnitude of measure-
ment variability is less than the minimal detectable change.
aAll r values are Spearman’s rank order correlation, and in all cases were significant with P < .0001.
Table 3. Validity Studies.a
Test Baseline Value
Correlation With 
FMA Total Score
Correlation With FMA 
Proximal Subscore
Correlation With FMA 
Hand/Wrist Subscore
Maximum grip force, affected/nonaffected hand 0.29 ± 0.22 0.74 0.73 0.73
Maximum pinch force, affected/non-affected hand 0.40 ± 0.30 0.88 0.87 0.85
Box & Blocks (no. of blocks) 0 (0-29) 0.86 0.79 0.88
ARAT score 27.2 ± 22.5 0.93 0.88 0.89
9-hole peg (no. of pegs placed) 0 (0-7) 0.75 0.64 0.80
SIS hand subscore 2.3 ± 1.3 0.86 0.79 0.88
Abbreviations: FMA, Fugl-Meyer Assessment; ARAT, Action Research Arm Test; SIS, Stroke Impact Scale.
aBaseline values are mean ± SD except for Box & Blocks and 9-hole peg scores, which are median (interquartile range). Spearman r values are pre-
sented for correlation values, which in all cases were significant with P < .0001. Mean FMA score across exams was 38 ± 15 points.
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± 3.2 for the wrist/hand FMA; none of these was signifi-
cantly different from zero, indicating that the students 
showed no significant differences from the answer key after 
training.
Ability of the Fugl-Meyer Assessment  
to Perform as a Stratifying Variable
The 66 patients had age 59.3 ± 14.1 years, time poststroke 
17 ± 34.6 months, gender 43 males/23 females, baseline 
total arm FMA = 36.9 ± 14.5 points, and change in FMA 3.8 
± 3.6 points. Baseline total arm FMA score was not linearly 
related to change in FMA score across arm robotic therapy 
(r = 0.15, P > .2); however, the second-degree polynomial 
relationship between these 2 measures was significant (r = 
0.47, P = .0001, Figure 1A), indicating a U-shaped relation-
ship. Consistent with this, the change in total arm FMA 
across therapy was significantly smaller for subjects with 
the lowest (FMA < 20) and for subjects the highest (FMA > 
55) baseline scores, as compared with the middle (P = .01 to 
P = .0002, see Figure 1B).
Implementation in a Clinical Stroke Trial
All 11 sites received the training materials and completed 
the requested FMA training prior to subject enrollment. 
There were no problems or issues reported at any study site 
with the implementation of this standardized FMA training 
procedure.
Discussion
A number of therapies are under study to improve motor 
outcome after stroke.3 The FMA has been a common 
choice for assessing treatment effects in this set-
ting.14,15,17-23,43 A need exists for a detailed approach to 
FMA scoring to maximize consistency over time and 
across sites, and for training materials for such a scoring 
approach. The current report describes such a detailed 
approach to FMA scoring (presented in full in the 
supplementary material available at http://nnr.sagepub 
.com/content/by/supplemental-data), then reviews experi-
ence with FMA training materials based on this approach. 
This approach was found to be reliable (Table 2) and valid 
Figure 1. (A) The change in total arm Fugl-Meyer Assessment (FMA) score across a period of arm motor robotic therapy is graphed 
as a function of baseline FMA score among 66 patients with chronic stroke. A linear relationship was not present (dashed line, r = 
0.15, P > .2). However, the second-degree polynomial relationship was significant (solid line, r = 0.47, P = .0001), indicating a U-shaped 
relationship, with the highest and lowest baseline FMA scores associated with the smallest treatment gains. (B) Further examination 
of the data from (A) supports the conclusion that the change in total arm FMA score across therapy differed significantly according to 
baseline score (P = .0001). Post hoc pairwise testing indicated that FMA gains were significantly smaller for the sixth of subjects with 
the lowest (FMA < 20) and for the sixth with the highest (FMA > 55) baseline scores, as compared with the middle two thirds (**P = 
.0002, *P = .01).
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(Table 3) across a range of measures, with good values for 
MDC. The current FMA training procedure was associ-
ated with significant improvements in the accuracy of 
FMA scoring and with reduced variance of FMA scoring, 
and the procedure was implemented within a phase II clin-
ical trial without incident, suggesting that such training 
may be useful for future trials. FMA gains across a period 
of arm motor therapy varied significantly in relation to the 
baseline FMA score, being smallest in subjects with the 
lowest and highest score, a finding that informs the issue 
of endpoint selection in restorative stroke trials.
The current study addresses the need for a standardized 
method to measure the FMA, with particular focus on the 
upper extremity. The original description of this scale by 
Fugl-Meyer et al6 provided limited details on many key 
operational aspects of testing and scoring. Given the 
increasing use of the FMA in restorative stroke tri-
als,14,15,17-23,43 a standardized scoring approach is needed to 
minimize subjectivity, maximize precision, and thereby 
insure that a score has the same meaning over space and 
time.39 Prior protocols for measuring FMA have been pub-
lished,24,25 but these did not always specify details critical to 
standardizing FMA scoring, such as the exact instructions 
that are provided to patients, initial limb position for testing, 
or the amount of assistance that the examiner can provide; 
did not include full training materials such as videos (see 
supplementary material available at http://nnr.sagepub 
.com/content/by/supplemental-data); and have been criti-
cized for introducing modifications of the original Fugl-
Meyer scale.44 The current standardized FMA scoring 
method and training procedure address these concerns. The 
current method was found to be reliable (Table 2), with ICC 
values 0.98 to 0.99, similar to those of Sullivan et al24 and 
Platz et al.45 Validity, examined in relation to wide-ranging 
motor assessments that considered the many dimensions by 
which stroke affects the motor system (Table 3), was also 
excellent and similar to prior findings.45 This remained true 
when FMA validity was measured in relation to patient-
reported outcomes, which have received attention for their 
ability to monitor care, facilitate communication, and 
improve patient compliance46-48; furthermore, one recent 
study found that the SIS, the patient-reported outcome mea-
sure examined in the current study (Table 3), can be a 
unique source of insight into arm motor status after stroke.49 
Reliability and validity findings were true for the total arm 
FMA, the FMA proximal subscore, and the FMA wrist/
hand (distal) subscore. The proximal FMA and the distal 
FMA subscores were included in analysis because some 
treatments selectively target the proximal or distal upper 
extremity. Thus, whereas proximal and distal arm FMA 
measures may not show separate dimensions in the setting 
of spontaneous stroke recovery,50 assessment of proximal 
arm separately from distal arm may be important to best 
capture51,52 or predict53 effects of some treatments. The 
training procedure improved consistency and accuracy of 
scoring. Together these findings support the utility of the 
current approach for measuring FMA.
The current findings have direct implications for clinical 
trials given that the current FMA standardized training pro-
cedure significantly reduced variance and improved accu-
racy in FMA scoring. Specifically, training was associated 
with a 20% decrease in the SD for the total arm FMA score. 
This level of reduction in variance of outcome measure 
scoring is not trivial: for a trial powered at 80% to detect a 
difference of 7 points on the total arm FMA between 2 treat-
ment groups, with α = .05, and with baseline SD of 14.5 (as 
in Table 1), a 20% reduction in variance would cut the total 
sample size needed to enroll from 137 to 88. The current 
FMA standardized training procedure improved accuracy: 
the students’ total arm FMA scores before training were sig-
nificantly different from answer key values, whereas stu-
dents’ scores after training did not differ from the answer 
key. The significant departure of FMA scores from the cor-
rect value prior to training would obfuscate detection of 
treatment effects. The MDC data provide further support 
that training with this approach is important to clinical tri-
als. The MDC
90
 for total arm FMA score using the current 
method was 3.2 points, indicating that a change of total arm 
FMA score greater than 3.2 points for an individual is nec-
essary to be 90% certain that the change is not because of 
measurement error. This value is substantially smaller than 
estimates for minimal clinically important difference for 
total arm FMA, which include 7.25 points (ie, half of a SD, 
across scales and populations54), 6.6 points (ie, 10% of the 
range for any given scale,55 10.6 to 19.8 points (ie, 16% to 
30% of the range, determined with respect to various upper 
extremity assessments in patients receiving inpatient reha-
bilitation 10-26 days after stroke56), 4.25 to 7.25 points (in 
patients an average of 59 months poststroke enrolled in a 
clinical trial, and depending on which aspect of motor func-
tion is used for comparison57), and 10 points (in patients 
receiving inpatient rehabilitation 17 days after stroke58). 
Clearly, for the FMA, as with many other measures, mini-
mal clinically important difference is context dependent,56 
for example, varying with the method used to define clini-
cal significance or with the population under study (eg, 
what constitutes a clinically important change is different 1 
week vs 1 year after stroke). The 3.2 point MDC
90
 value is 
also smaller than many treatment effects measured by the 
total arm FMA, for example, 25 points with amphetamine 
initiated 8 days after stroke,14 34 points with fluoxetine ini-
tiated 9 days after stroke,15 or 8 to 9 points in studies of 
robotic therapy enrolling patients months/years after stroke 
onset.16,17
The change in total arm FMA score associated with robot 
therapy had a second-order (quadratic), rather than a linear, 
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relationship with baseline FMA score (Figure 1), a finding 
that informs the use of the FMA as an endpoint in studies 
enrolling patients with a broad range of motor deficits. 
There are several possible explanations for this finding, 
including that the FMA is not truly linear. Fugl-Meyer et al6 
based FMA scoring on the sequence of stages of spontane-
ous recovery,7-9 but this succession is not truly linear, and so 
a FMA increase from 10 to 20 points does not necessarily 
have the same meaning as an increase from 50 to 60 points. 
Also, the FMA may have a floor and ceiling effect. The lit-
erature is divided on this point,11,29-31 possibly because it 
might be more true in some contexts more than others. 
Figure 1 suggests floor and ceiling effects may be present 
when using the FMA to measure change associated with 
robotic therapy. Regardless of the explanation, the lack of a 
linear relationship between baseline total arm FMA score 
and the FMA score change with treatment suggests that 
MDC and minimal clinically important difference might 
vary according to the population under study, a perspective 
arising frequently in studies of stroke given the heterogene-
ity of this population.
How might future trials using FMA as an endpoint build 
on the current finding that the relationship between base-
line FMA and change in FMA is quadratic not linear? For 
trials that evaluate treatment response dichotomously, that 
is, as successful or not, one potential response is to define 
a successful outcome in a manner that varies with baseline 
status. This approach is known as a sliding dichotomous 
outcome, or responder analysis. A recent analysis of acute 
stroke trial outcome measures emphasized the utility of 
this approach,59 and noted its ability to increase study 
power. With this approach, patient subgroups are specified 
before the trial on the basis of established prognostic mea-
sures such as age, baseline behavioral status, or extent of 
injury. Successful response to therapy is defined differently 
for each subgroup. A sliding outcomes approach has been 
used in several acute stroke trials.59 For example, the 
AbESTT-II trial of Abciximab for acute stroke defined 
good outcome as modified Rankin Scale (mRS) score of 0 
for patients with baseline National Institutes of Health 
Stroke Scale (NIHSS) score of 4 to 7, mRS score of 0 to 1 
for baseline NIHSS of 8 to 14, and mRS score of 0 to 2 for 
baseline NIHSS 15 to 22.60 A sliding outcomes approach 
has also been used in the chronic stroke. For example, the 
LEAPS trial of locomotor training61 defined success in the 
primary outcome measure (proportion of participants with 
improved functional walking level) as gait velocity ≥0.4 
m/s for enrollees with baseline gait velocity <0.4 m/s and 
as gait velocity ≥0.8 m/s for enrollees with baseline gait 
velocity 0.4 to 0.8 m/s.
The value and logic of using a sliding dichotomous 
(responder) analysis in the context of arm motor recovery is 
readily appreciated—return of rapid dexterous hand move-
ments might be extremely unlikely in a patient with severe 
arm motor deficits at baseline, but a boost in grip force of a 
mere 20 N might be attainable and indeed relevant to func-
tion, whereas the same 20 N boost in grip force might be 
near trivial for a patient with mild baseline deficits. The cur-
rent results (Figure 1) suggest utility for sliding dichoto-
mous outcomes in clinical trials targeting arm motor 
function. In such trials, patients at the extremes of arm 
motor function might define therapeutic success using a dif-
ferent FMA cutoff—or perhaps even using a different 
scale—as compared with patients with intermediate levels 
of arm motor function. The exact choice of cutoffs may 
vary depending on the population and intervention under 
study. An alternative approach for dealing with the hetero-
geneity in stroke populations is to use a composite endpoint, 
as was employed in the Everest trial of epidural motor cor-
tex stimulation,62,63 where the primary outcome measure 
combined the impairment-based FMA with a second scale 
(Arm Motor Ability Test) that measured function. The FMA 
has limited sensitivity to motor-related measures such as 
executive control, timing, and imagery, and so the choice of 
a second scale for a composite endpoint might be guided by 
the content of the therapeutic intervention.
The current report described then assessed an approach 
to maximize utility of the FMA for stroke recovery. 
Limitations of the study include that validity and reliability 
of the current FMA approach might vary across different 
populations of patients, such as those with severe aphasia or 
severe neglect or very mild motor deficits, or across differ-
ent examiners. The reliability data, as in any study of neuro-
logically infirm populations, must be interpreted in light of 
the potential influence of factors such as fatigue, medica-
tion effects, and confusion. Also, the current method stan-
dardized training procedure has not been validated outside 
the English language. The current approach increases accu-
racy of FMA scoring and so would be expected to improve 
precision and statistical power in clinical trials that use the 
FMA as an endpoint.
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